But with Novartis failing to convince European regulators about the merits of Xiidra last year, and Allergan's ageing Restasis potentially ... a phase 3 trial for eye drops containing tivanisiran ...

and five patents relating to Restasis. The spokesperson added: “Allergan wants its patents to be enforced against infringers, (makers of generic eye drops) but in federal court, not in the IPR ...